Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 5,860,000 shares, an increase of 19.3% from the October 15th total of 4,910,000 shares. Based on an average daily volume of 504,200 shares, the days-to-cover ratio is currently 11.6 days. Approximately 13.3% of the shares of the company are short sold.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS traded down $0.09 during trading hours on Friday, reaching $4.19. The stock had a trading volume of 793,622 shares, compared to its average volume of 750,478. The business's fifty day moving average is $3.69 and its two-hundred day moving average is $3.65. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Sell-side analysts expect that Pyxis Oncology will post -1.03 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC bought a new position in Pyxis Oncology during the second quarter valued at $40,000. Intech Investment Management LLC purchased a new position in Pyxis Oncology in the 3rd quarter valued at $55,000. SG Americas Securities LLC purchased a new position in Pyxis Oncology in the third quarter worth approximately $58,000. The Manufacturers Life Insurance Company acquired a new position in shares of Pyxis Oncology in the second quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC increased its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company's stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company's stock.

Analyst Upgrades and Downgrades

PYXS has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a "buy" rating and a $10.00 price objective on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They set an "overweight" rating and a $13.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Pyxis Oncology has a consensus rating of "Buy" and an average price target of $9.57.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.